Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + bortezomib-based induction/consolidation vs VTd, with ixazomib ± daratumumab maintenance in transplant-eligible newly diagnosed multiple myeloma
2024-511781-37-00Phase 2Authorised
- Sponsor
- European Myeloma Network
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of daratumumab, bortezomib, ixazomib, cyclophosphamide, thalidomide and 1 more in multiple myeloma (MM) (4 arms), sponsored by European Myeloma Network. Primary endpoints: Progression-free survival (PFS) - Part 1, Progression-free survival (PFS) - Part 2 and 1 more. Planned start Jun 2024; status: authorised.
02
Drugs
daratumumabbortezomibixazomibcyclophosphamidethalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-511781-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511781-37-00.